John B. Hawken

Amministratore Delegato presso Immutep SAS

76 anni

Consumer Services

Health Technology

Profilo

John B.
Hawken is currently the Co-Chief Executive Officer at Immutep SAS since 2010.
Previously, he worked as a Principal at Aptanomics SA. He completed his undergraduate degree at the University of Oxford and holds an MBA from INSEAD.

Posizioni attive di John B. Hawken

Società	Posizione	Inizio
Immutep SAS Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France.	Amministratore Delegato	02/12/2003

Tutte le posizioni attive di John B. Hawken

Precedenti posizioni note di John B. Hawken

Società	Posizione	Fine
Aptanomics SA Aptanomics SA Pharmaceuticals: MajorHealth Technology Aptanomics SA discovers and develops new drugs in major markets of unmet medical need. Its proprietary discovery engine, based on peptide aptamers, delivers a regular flow of new hits against relevant industrial targets. Aptanomics offers opportunities for drug discovery collaborations leveraging the peptide aptamer technology to identify new druggable sites and screen for small molecule hits. The company was founded by Roger Brent, Pierre Colas and Johm B. Hawken in 2001 and is headquarters in Lyon, France	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di John B. Hawken

Formazione di John B. Hawken

University of Oxford	Undergraduate Degree
INSEAD	Masters Business Admin

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di John B. Hawken

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Immutep SAS Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France.	Health Technology
Aptanomics SA Aptanomics SA Pharmaceuticals: MajorHealth Technology Aptanomics SA discovers and develops new drugs in major markets of unmet medical need. Its proprietary discovery engine, based on peptide aptamers, delivers a regular flow of new hits against relevant industrial targets. Aptanomics offers opportunities for drug discovery collaborations leveraging the peptide aptamer technology to identify new druggable sites and screen for small molecule hits. The company was founded by Roger Brent, Pierre Colas and Johm B. Hawken in 2001 and is headquarters in Lyon, France	Health Technology